A phase 1, 2-part, randomized, subject and investigator blinded, placebo-controlled, cross-over trial to evaluate the safety, tolerability and pharmacokinetics Of CE-326,597 in obese, adult subjects with asymptomatic cholelithiasis.

Trial Profile

A phase 1, 2-part, randomized, subject and investigator blinded, placebo-controlled, cross-over trial to evaluate the safety, tolerability and pharmacokinetics Of CE-326,597 in obese, adult subjects with asymptomatic cholelithiasis.

Completed
Phase of Trial: Phase I

Latest Information Update: 20 Jan 2010

At a glance

  • Drugs CE 326597 (Primary)
  • Indications Obesity
  • Focus Adverse reactions; Pharmacokinetics
  • Most Recent Events

    • 14 Nov 2008 Status changed from active, no longer recruiting to completed as reported by ClinicalTrials.gov.
    • 23 Oct 2008 Status changed from recruiting to active, no longer recruiting as reported by ClinicalTrials.gov.
    • 23 Jan 2008 Status changed from initiated to recruiting.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top